Sven Mahner Selected Research

Bevacizumab (Avastin)

12/2023	Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR 11/ICON-7.
1/2023	Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.
1/2020	Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
7/2017	Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.
1/2015	Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer.
4/2013	Gastropleural fistula in a patient with recurrent ovarian cancer receiving combination therapy with Carboplatin, gemcitabine, and bevacizumab.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sven Mahner Research Topics

Disease

133	Neoplasms (Cancer) 05/2024 - 10/2006
102	Ovarian Neoplasms (Ovarian Cancer) 05/2024 - 07/2009
47	Breast Neoplasms (Breast Cancer) 09/2023 - 10/2006
34	Ovarian Epithelial Carcinoma 05/2024 - 07/2009
26	Uterine Cervical Neoplasms (Cancer of the Cervix) 05/2024 - 01/2011
22	Vulvar Neoplasms (Vulvar Cancer) 02/2024 - 05/2010
20	Neoplasm Metastasis (Metastasis) 07/2023 - 07/2009
18	Carcinoma (Carcinomatosis) 12/2023 - 04/2012
15	Carcinogenesis 01/2024 - 10/2013
12	Habitual Abortion (Recurrent Miscarriage) 01/2022 - 01/2018
10	Disease Progression 07/2023 - 01/2015
9	Spontaneous Abortion (Miscarriage) 01/2022 - 01/2018
8	Gestational Diabetes (Gestational Diabetes Mellitus) 11/2023 - 07/2017
8	Residual Neoplasm 01/2023 - 02/2009
8	Endometrial Neoplasms (Endometrial Cancer) 01/2023 - 03/2016
8	Pre-Eclampsia (Preeclampsia) 01/2022 - 07/2017
8	Ascites 01/2021 - 09/2009
7	Circulating Neoplastic Cells 05/2024 - 01/2017
6	Inflammation (Inflammations) 03/2024 - 03/2020
5	Peritoneal Neoplasms 03/2023 - 04/2013
5	Fetal Growth Retardation (Intrauterine Growth Retardation) 01/2019 - 12/2015
5	Neutropenia 01/2018 - 01/2015
4	Endometriosis 01/2024 - 07/2017
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2024 - 03/2015
4	Lymphatic Metastasis 01/2021 - 05/2010
4	Alopecia (Baldness) 04/2020 - 01/2015
3	Uterine Cervical Dysplasia 08/2023 - 01/2017
3	Pain (Aches) 08/2021 - 05/2019
3	Rupture 05/2019 - 07/2013
3	Thrombocytopenia (Thrombopenia) 01/2018 - 12/2016

Drug/Important Bio-Agent (IBA)

46	PlatinumIBA 05/2024 - 01/2010
38	Proteins (Proteins, Gene)FDA Link 03/2024 - 07/2009
25	Biomarkers (Surrogate Marker)IBA 02/2024 - 01/2013
12	Estrogen ReceptorsIBA 09/2023 - 09/2012
10	Messenger RNA (mRNA)IBA 05/2024 - 09/2015
10	Hormones (Hormone)IBA 08/2021 - 01/2017
9	Galectins (Galectin)IBA 03/2024 - 12/2015
9	Dinoprostone (PGE2)FDA Link 07/2023 - 01/2018
9	Carboplatin (JM8)FDA LinkGeneric 01/2023 - 09/2009
9	ParaffinIBA 01/2022 - 02/2013
7	Paclitaxel (Taxol)FDA LinkGeneric 01/2023 - 01/2015
7	EnzymesIBA 11/2021 - 01/2011
7	Gemcitabine FDA Link 10/2020 - 04/2013
6	Bevacizumab (Avastin)FDA Link 12/2023 - 04/2013
6	RNA (Ribonucleic Acid)IBA 01/2023 - 11/2010
6	niraparibIBA 01/2023 - 12/2016
6	histone H3 trimethyl Lys4IBA 01/2022 - 03/2020
6	CytokinesIBA 11/2021 - 10/2020
6	Estrogens (Estrogen)FDA Link 01/2021 - 09/2012
5	LigandsIBA 12/2023 - 01/2019
5	GTP-Binding Proteins (G-Protein)IBA 09/2023 - 01/2018
5	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 09/2023 - 11/2017
5	CateninsIBA 01/2023 - 05/2017
5	AntibodiesIBA 10/2021 - 05/2010
5	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2016
5	ProstaglandinsIBA 12/2020 - 07/2017
4	TeaIBA 09/2023 - 01/2019
4	Co-Repressor ProteinsIBA 09/2023 - 01/2019
4	Topotecan (Hycamtin)FDA LinkGeneric 08/2023 - 01/2011
4	AntigensIBA 01/2023 - 10/2018
4	CA-19-9 Antigen (CA 19-9 Antigen)IBA 12/2022 - 01/2017
4	Mucin-1 (CA 15-3 Antigen)IBA 10/2022 - 01/2019
4	Lysine (L-Lysine)FDA Link 11/2021 - 03/2020
4	Histones (Histone)IBA 11/2021 - 12/2017
4	Prostaglandin Receptors (Prostaglandin Receptor)IBA 03/2021 - 07/2017
4	Thyroid Hormone Receptors (Thyroid Hormone Receptor)IBA 01/2021 - 01/2020
4	Protein Isoforms (Isoforms)IBA 01/2021 - 06/2020
4	Calcitriol Receptors (Calcitriol Receptor)IBA 10/2020 - 11/2017
4	Docetaxel (Taxotere)FDA Link 10/2018 - 09/2009
4	Carbonic Anhydrase IXIBA 01/2011 - 05/2010
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2023 - 01/2015
3	progesterone receptor AIBA 02/2023 - 01/2019
3	olaparibIBA 01/2023 - 01/2015
3	Thromboplastin (Tissue Factor)IBA 01/2023 - 01/2016
3	Sialyl Lewis X AntigenIBA 12/2022 - 01/2017
3	Progesterone Receptors (Progesterone Receptor)IBA 03/2022 - 01/2019
3	Cadherins (E-Cadherin)IBA 01/2022 - 09/2015
3	Small Interfering RNA (siRNA)IBA 11/2021 - 01/2020
3	Thyroid HormonesIBA 08/2021 - 02/2018
3	Bromodeoxyuridine (BrdU)IBA 03/2021 - 03/2020
3	CarbohydratesIBA 01/2021 - 06/2017
3	Indicators and Reagents (Reagents)IBA 01/2021 - 07/2019
3	AnthracyclinesIBA 10/2020 - 11/2016
3	Vitamin D FDA LinkGeneric 10/2020 - 11/2017
3	Plasminogen Activator Inhibitor 1IBA 09/2020 - 11/2010
3	Formaldehyde (Formol)FDA Link 07/2020 - 09/2017
3	liposomal doxorubicin (Doxil)FDA Link 01/2020 - 02/2015
3	Galectin 1 (LGALS1)IBA 10/2019 - 04/2016
3	Carrier Proteins (Binding Protein)IBA 01/2018 - 01/2013

Therapy/Procedure

73	Therapeutics 05/2024 - 02/2009
48	Drug Therapy (Chemotherapy) 01/2023 - 02/2009
10	Cytoreduction Surgical Procedures 01/2023 - 07/2009
9	Radiotherapy 01/2023 - 04/2012
9	Lymph Node Excision (Lymph Node Dissection) 01/2022 - 05/2013
6	Adjuvant Radiotherapy 01/2022 - 12/2011
6	Adjuvant Chemotherapy 08/2021 - 05/2016
3	Hysterectomy 05/2024 - 10/2023
3	Duration of Therapy 01/2023 - 08/2021
3	Immunotherapy 07/2021 - 12/2019
3	Neoadjuvant Therapy 10/2019 - 09/2009